Abstract
Background: The term Alcohol Use Disorder (AUD) incorporates different states of disease related to the recurrent use of alcohol and linked to the relevant impairment, disability and failure to perform major responsibilities in different realms. Many neurotransmitter systems are involved in the phases or states of alcoholism from reward mechanisms, associated to binge intoxication, to stress and anxiety linked to relapse and withdrawal. Some neuropeptides play a key function in the control of anxiety and stress, and establish a close relationship with the pathological mechanisms underlying alcohol addiction. Among them, Neuropeptide Y (NPY), Corticotropin-releasing factor (CRF)/Urocortins and Neuropeptide S (NPS) cross-talk, and are responsible for some of the maladaptation processes that the brain exhibits during the progression of the disease.
Method: In this study, we review the literature mainly focused on the participation of these neuropeptides in the pathophysiology of AUD, as well as on the use of antagonists designed to investigate signaling mechanisms initiated after ligand binding and their connection to biochemical adaptation events coupled to alcohol addiction. The possibility that these systems may serve as therapeutic objectives to mitigate or eliminate the harm that drinking ethanol generates, is also discussed. Conclusion: The peptide systems reviewed here, together with other neurotransmitter systems and their mutual relationships, are firm candidates to be targeted to treat AUD.Keywords: Alcohol use disorder (AUD), alcoholism, neuropeptide Y, corticotropin- releasing factor (CRF), neuropeptide S (NPS), urocortin I, neuropeptide antagonists.
Current Medicinal Chemistry
Title:Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD)
Volume: 24 Issue: 23
Author(s): Francisco D. Rodriguez*Rafael Coveñas
Affiliation:
- Department of Biochemistry and Molecular Biology, Group GIR-BMD, Faculty of Chemistry, University of Salamanca, 37001 Salamanca,Spain
Keywords: Alcohol use disorder (AUD), alcoholism, neuropeptide Y, corticotropin- releasing factor (CRF), neuropeptide S (NPS), urocortin I, neuropeptide antagonists.
Abstract: Background: The term Alcohol Use Disorder (AUD) incorporates different states of disease related to the recurrent use of alcohol and linked to the relevant impairment, disability and failure to perform major responsibilities in different realms. Many neurotransmitter systems are involved in the phases or states of alcoholism from reward mechanisms, associated to binge intoxication, to stress and anxiety linked to relapse and withdrawal. Some neuropeptides play a key function in the control of anxiety and stress, and establish a close relationship with the pathological mechanisms underlying alcohol addiction. Among them, Neuropeptide Y (NPY), Corticotropin-releasing factor (CRF)/Urocortins and Neuropeptide S (NPS) cross-talk, and are responsible for some of the maladaptation processes that the brain exhibits during the progression of the disease.
Method: In this study, we review the literature mainly focused on the participation of these neuropeptides in the pathophysiology of AUD, as well as on the use of antagonists designed to investigate signaling mechanisms initiated after ligand binding and their connection to biochemical adaptation events coupled to alcohol addiction. The possibility that these systems may serve as therapeutic objectives to mitigate or eliminate the harm that drinking ethanol generates, is also discussed. Conclusion: The peptide systems reviewed here, together with other neurotransmitter systems and their mutual relationships, are firm candidates to be targeted to treat AUD.Export Options
About this article
Cite this article as:
Rodriguez D. Francisco *, Coveñas Rafael , Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD), Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170316120836
DOI https://dx.doi.org/10.2174/0929867324666170316120836 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Genomics Approach for Identification of Molecular Processes Underlying Neurodegenerative Disorders in Prion Diseases
Current Genomics The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Association between Antiretroviral Treatment and Markers of Systemic Inflammation among HIV Patients in Ghana
Current HIV Research Minocycline Mediated Mitochondrial Cytoprotection: Premises for Therapy of Cerebrovascular and Neurodegenerative Diseases
Current Drug Targets Cardiac Imaging in Heart Failure with Comorbidities
Current Cardiology Reviews Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Embryonic Signaling Pathways as Potential Targets for the Treatment of Rhabdomyosarcoma)
Current Drug Targets Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?
Recent Patents on Cardiovascular Drug Discovery Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy Rectifying Attenuated Store-Operated Calcium Entry as a Therapeutic Approach for Alzheimer’s Disease
Current Alzheimer Research Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update
Mini-Reviews in Medicinal Chemistry Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles
Current Alzheimer Research Implications of Klotho Protein for Managing Kidney Disease - an Emerging Role in Therapeutics and Molecular Medicine
Current Molecular Medicine Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection
Current Neuropharmacology Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets